KETAMINE shows promise in managing levodopa-induced dyskinesia by disrupting abnormal brain activity and promoting lasting neuroplasticity, new research has shown. Levodopa-induced dyskinesia is a ...

A new clinical trial, sponsored by UCL and UCLH, aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile ...

Tardive dyskinesia is a drug-induced neurological disorder characterized by involuntary movements of the face and body. The condition develops as a side effect of long-term use of antipsychotics and ...